Phase 1/2Terminated
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients With Previously Treated Advanced Pancreatic Cancer
- Sponsor
- Helix BioPharma Corporation (Industry)
- Enrollment
- 28 enrolled
- Conditions
- Pancreas Cancer
- Interventions
- L-DOS47; Doxorubicin
- Ages
- adults, older adults
- Registry
- NCT04203641
Full record on ClinicalTrials.gov
From the registry
This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.
Primary outcomes
- Number of complete plus partial responders as per RECIST version 1.1
- Adverse events (as per CTCAE v. 5.0)
History
Last registry update
Primary completion
Registered
Started